Skip to content

CalAmp CAMP Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
Polaryx Therapeutics, Inc.
 logo
Polaryx Therapeutics, Inc. PLYX
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by CalAmp in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's accrued liabilities, current?
CalAmp (CAMP) reported accrued liabilities, current of $4.3M in Q1 2026.
How has CalAmp's accrued liabilities, current changed year-over-year?
CalAmp's accrued liabilities, current increased by 134.1% year-over-year, from $1.84M to $4.3M.
What is the long-term trend for CalAmp's accrued liabilities, current?
Over 2 years (2023 to 2025), CalAmp's accrued liabilities, current has grown at a 30.9% compound annual growth rate (CAGR), from $3.3M to $5.66M.